EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody

Peggy A Birikorang iD, Dominic M Menendez, Robert Edinger, Gary Kohanbash, W Barry Edwards

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Peggy A Birikorang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Missouri-Columbia, 503 S College Avenue, Columbia, Missouri 65211, United States. Hauptthemen laut MEDLINE: Antibodies, Bispecific, CD11b Antigen, Receptor, EphA2, Immunoconjugates. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting molecules, such as antibodies and peptides, play a key role in the precise delivery of cytotoxic payloads to tumor sites by binding to specific tumor-associated antigens or other proteins within the tumor microenvironment. This investigation evaluates the potential therapeutic application of a bispecific antibody (BsAb), which simultaneously targets EphA2, a tumor-associated antigen, and CD11b, a protein expressed by tumor-associated macrophages and myeloid-derived suppressor cells (TAMCs). Recombinantly produced anti-EphA2-CD11b-BsAb was conjugated to a bifunctional chelator, NOTA-SCN, and then radiolabeled with copper-64 (64Cu). The [64Cu]Cu-NOTA-anti-EphA2-CD11b-BsAb radioimmunoconjugate was subsequently administered to HT1080-fibrosarcoma-bearing nude mice via tail vein injection. Positron Emission Tomography (PET) and ex vivo biodistribution analyses were performed to determine tumor uptake and pharmacokinetic localization. At 4, 24, and 48 h postinjection (p.i.), the percent injected dose per gram (%ID/g) of [64Cu]Cu-NOTA-anti-EphA2-CD11b-BsAb in HT1080 xenografts were 5.35 ± 2.24, 4.44 ± 1.90, and 4.10 ± 0.60, respectively. There was high uptake in the liver as well as in CD11b-expressing organs, including the spleen, bone marrow, and lung. Binding in these CD11b-rich organs was significantly reduced by coadministering the dose with nonradiolabeled anti-CD11b-IgG and anti-EphA2-CD11b-BsAb, with a concurrent increase in tumor uptake compared to nonblocked mice (8.39 ± 1.37%ID/g for blocked and 4.44 ± 1.90%ID/g for nonblocked at 24 h p.i., p = 0.0175). Further optimization studies showed that at lower molar activity (3.7 MBq/nmol, 100 μCi/nmol), there were significantly higher tumor accumulations and reduced uptake in CD11b-expressing organs compared to higher molar activity (22.2 MBq/nmol, 600 μCi/nmol). Anti-EphA2-CD11b-BsAb is a functional targeting molecule and would require optimization through molar activity or blocking with nonradiolabeled antibody to maximize tumor targeting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificCD11b AntigenReceptor, EphA2ImmunoconjugatesAnimalsHumansMiceTissue DistributionCell Line, TumorCopper RadioisotopesMice, NudePositron-Emission Tomography

Substanzen

Antibodies, BispecificCD11b AntigenReceptor, EphA2Copper RadioisotopesCopper-64ImmunoconjugatesEPHA2 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry, University of Missouri-Columbia, 503 S College Avenue, Columbia, Missouri 65211, United States.
  • Molecular Imaging and Theranostics Center, University of Missouri-Columbia, 1514 Research Park Drive, Columbia, Missouri 65203, United States.
  • Department of Radiation Oncology, University of Pittsburgh, 200 Lothrop Street, Pittsburgh, Pennsylvania 15213, United States.
  • Department of Neurological Surgery, University of Pittsburgh, 503 45th Street, Pittsburgh, Pennsylvania 15201, United States.
  • Department of Chemistry, University of Missouri-Columbia, 601 S College Avenue, Columbia, Missouri 65211, United States.

ORCID-Profile: Peggy A Birikorang

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Birikorang, P. A., Menendez, D. M., Edinger, R., Kohanbash, G., & Edwards, W. B. (2025). Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00070

Vancouver

Birikorang PA, Menendez DM, Edinger R, Kohanbash G, Edwards WB. Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00070

BibTeX
@article{Birikorang2025,
  author = {Birikorang, Peggy A and Menendez, Dominic M and Edinger, Robert and Kohanbash, Gary and Edwards, W Barry},
  title = {Developing and Characterizing the Tumor-Targeting Efficiency of an Anti-EphA2-CD11b Bispecific Antibody},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00070}
}
Kostenlos starten →